Ellen Wolff

Project Lead / Health Economist (samordnare) at The Dental and Pharmaceutical Benefits Agency, TLV

Ellen Wolff is a seasoned health economist with extensive experience in various roles within health organizations. Currently serving as a Senior Health Economist on secondment at Folkhälsomyndigheten since April 2024, Ellen also holds the position of Project Lead / Health Economist at Tandvårds- och läkemedelsförmånsverket, TLV, since September 2022. Previous roles include Acting Head of Unit for Analysis and Health Economist at Folkhälsomyndigheten from September 2014 to September 2022, and Health Economist at TLV from September 2013 to September 2014. Ellen holds a PhD in Health Economics from the University of Gothenburg, a Master of Science in Economics from the same institution, and a Politisk Kandidat examen in Economics from Lund University.

Location

Stockholm, Sweden

Links

Previous companies


Org chart

No direct reports

Teams

This person is not in any teams


Offices


The Dental and Pharmaceutical Benefits Agency, TLV

The Dental and Pharmaceutical Benefits Agency, TLV, is a central government agency whose remit is to determine whether a pharmaceutical product or dental care procedure shall be subsidized by the state. Our duty is to examine which medicines, medical devices and dental care treatments will be subsidised by society. We also contribute to quality service and accessibility of pharmacies. Our duty is to examine which medicines, medical devices and dental care treatments will be subsidised by society.In addition to examining new medicines, we also work systematically to evaluate the medicines included in the high-cost threshold to determine whether their reimbursement should be maintained or restricted. On the pharmacy market our remit is to create the conditions for quality service and accessibility at pharmacies. We do this partly through the generic substitution system, the retail margin for pharmacies and by monitoring the pharmacy market. Furthermore, we decide how much a medicine or a medical device in the high-cost threshold should cost. And, we determine what margin pharmacies should use when selling products, meaning the difference between the wholesale and retail prices. We determine the pricing for new dosage forms, strengths and packaging and examine whether they should be included in the high-cost threshold.


Headquarters

Stockholm, Sweden

Employees

51-200

Links